Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenue
Orthopaedic product sales	$ 71,814	$ 82,513
Other revenue	389	99
Total Revenue	72,203	82,612
Cost of Sales	28,717	32,511
Gross Profit	43,486	50,101
Operating Expenses
General and administrative	12,881	15,246
Sales and marketing	32,059	40,511
Research and development	1,702	2,441
Depreciation and amortization	4,118	5,485
Impairment of goodwill and intangible assets	48,146	17,586
Restructuring expenses	2,970	4,680
Separation related expenses	1,568	1,901
Non-cash consulting expense	120	85
Total Operating Expenses	103,564	87,935
Loss from Operations	(60,078)	(37,834)
Other Income (Expense)
Interest expense	(10,145)	(14,705)
Change in warrant derivative liability	121	203
Other income (expense)	3	(75)
Total Other Expense	(10,021)	(14,577)
Net Loss from Operations Before Provision for Income Taxes	(70,099)	(52,411)
Provision for Income Taxes
Current and Deferred
Net Loss	$ (70,099)	$ (52,411)
Net loss per share:
Basic	$ (5.97)	$ (34.76)
Dilutive	$ (5.97)	$ (34.76)
Shares used in the computation:
Basic	11,740,550	1,507,769
Dilutive	11,740,550	1,507,769